Top Back to top

Graft-versus-Host Disease after donor-derived chimeric antigen receptor T-cell infusion post allogeneic HSCT

Transplant Complications Working Party (TCWP)
Cellular Therapy & Immunobiology Working Party (CTIWP)
Study type:
Study number:
Type of Stem Cell Treatment:
Short title:
Chronic GVHD over time
Primary objective:
To determine cumulative incidence of acute and chronic GvHD at 100 and 365 days, after donor-derived CAR T-cell infusion post allo-HSCT.
Key inclusion criteria:
Recipients of Allogeneic HSCT; Disease Relapse after Allogeneic HSCT; Donor derived CAR T-cell infusion after Allogeneic HSCT.
Principal investigator:
Guillermo Ortí